Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 248-514-6 | CAS number: 27538-10-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- GLP compliance:
- yes
- Test type:
- fixed dose procedure
Test material
- Reference substance name:
- 2-ethyl-4-hydroxy-5-methylfuran-3(2H)-one
- EC Number:
- 248-514-6
- EC Name:
- 2-ethyl-4-hydroxy-5-methylfuran-3(2H)-one
- Cas Number:
- 27538-10-9
- Molecular formula:
- C7H10O3
- IUPAC Name:
- 2-ethyl-4-hydroxy-5-methylfuran-3(2H)-one
1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- No. of animals per sex per dose:
- 3 females
Results and discussion
Effect levels
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 300 - < 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Mortality of 2/3 females at limit dose of 2000 mg/kg body weight was noted. One female was sacrificed for human reasons. All 6/6 females survived the dose of 300 mg/kg body weight
- Clinical signs:
- Test item-related mortality in females treated with the test item in dose of 2000 mg/kg body weight was observed within few minutes after administration of the test item. Immediately after administration of the test item, lethargy was observed in animal No 3, animals No 1 and No 2 were sleepy and it persisted to the next day. Dyspnea was observed in animals No 1 and No 2 within first 30 minutes. Animal No 3 died in a few minutes after administration of the test item, animal No 2 was found dead on the next day and animal No 1 was euthanised for human reasons.
No mortality was observed in females treated with the test item at dose of 300 mg/kg body weight. During the follow up period, no animals displayed signs of intoxication, change of health, nor any other adverse reaction negative reactions. - Body weight:
- The body weights of all animals treated with the dose of 300 mg/kg increased during the study. A slight decrease in body weights in animals No 4 and No 8 and a stagnation of body weights in animal No 6 and No 7 were observed between the first and second week after administration.
- Gross pathology:
- All animals were necropsied. Animal No 2 could not be necropsied because cadaver was autolysed. Blood in gastrointestinal tract and diffusely altered the colour of the of stomach mucosa were registered in animal No 1 which was sacrificed.
All animals treated with dose of 300 mg/kg body weight were necropsied. During necropsy, no macroscopic findings were noticed.
Any other information on results incl. tables
Table1Administration Results
Sex |
Dose |
ID |
Result |
Sex |
Dose |
ID |
Result |
♀ |
2000 mg/kg |
1 |
euthanasia |
♀ |
300 mg/kg |
4 |
alive |
2 |
dead |
5 |
alive |
||||
3 |
dead |
6 |
alive |
||||
- |
- |
7 |
alive |
||||
- |
- |
8 |
alive |
||||
- |
- |
9 |
alive |
Table2Clinical Observation
Observation |
Time After Administration |
||||||||||||||||||
Hour |
Day |
||||||||||||||||||
I |
0.5 |
1 |
2 |
4 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|
Skin and Hair |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Eyes |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Mucosa |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Respiratory System |
- |
No 2, 1* |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Circulatory System |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
CNS |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Somatomotoric Activity |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Tremor |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Spasms |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Salivation |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Diarrhoea |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Lethargy |
No 3 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Sleep |
No 2, 1 |
No 2, 1 |
No 2, 1 |
No 2, 1 |
No 2, 1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Coma |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Death |
No 3 |
- |
- |
- |
- |
No 2 No 1** |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
I-Immediately,-No observed signs, *- dyspnea, **- euthanasia
Table3Body Weight
Sex |
Dose |
ID |
Body Weight (g) |
Body Weight Difference (g) |
||||
Initial |
Week 1 |
Week 2 |
Week 1 - Initial |
Week 2 - Initial |
Week 2 - Week 1 |
|||
♀ |
2000 mg/kg |
1 |
160 |
- |
- |
- |
- |
- |
2 |
177 |
- |
- |
- |
- |
- |
||
3 |
160 |
- |
- |
- |
- |
- |
||
300 mg/kg |
4 |
200 |
221 |
215 |
21 |
15 |
- 6 |
|
5 |
202 |
207 |
209 |
5 |
7 |
2 |
||
6 |
197 |
209 |
209 |
12 |
12 |
0 |
||
7 |
203 |
227 |
227 |
24 |
24 |
0 |
||
8 |
201 |
214 |
209 |
13 |
8 |
-5 |
||
9 |
197 |
211 |
216 |
14 |
19 |
5 |
Table4Necropsy Results
Sex |
Dose |
ID |
Result |
Sex |
Dose |
ID |
Result |
♀ |
2000 mg/kg |
1 |
blood in GIT red colour of stomach mucosa |
♀ |
300 mg/kg |
4 |
no finding |
2 |
autolytic changes |
5 |
no finding |
||||
3 |
no finding |
6 |
no finding |
||||
- |
- |
7 |
no finding |
||||
- |
- |
8 |
no finding |
||||
- |
- |
9 |
no finding |
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The LD50 of the test item Furanone Homo is higher than 300 mg/kg body weight and lower than 2000 mg/kg body weight after single oral administration to Wistar rats.
Based on Annex 2d Test Procedure with a Starting Dose of 2000 mg/kg body weight of OECD Guideline 423 it can be concluded that the test item Furanone Homo is according to UN Globally Harmonized System of Classification, Labelling and Packaging of Chemicals classified Category 4 with a LD50 cut off value 500 mg/kg body weight according to Regulation (EU) Nr. 1272/2008 (CLP), after single oral administration to Wistar rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.